Details for Patent: 11,045,461
✉ Email this page to a colleague
Which drugs does patent 11,045,461 protect, and when does it expire?
Patent 11,045,461 protects XOLREMDI and is included in one NDA.
This patent has twelve patent family members in twelve countries.
Summary for Patent: 11,045,461
| Title: | Compositions of CXCR4 inhibitors and methods of preparation and use |
| Abstract: | The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4. |
| Inventor(s): | Brands Karel Marie Joseph |
| Assignee: | X4 PHARMACEUTICALS, INC. |
| Application Number: | US16704302 |
|
Patent Claim Types: see list of patent claims | |
| Scope and claims summary: | United States Patent 11,045,461: An Examination of Scope and Claims In this article, we delve into the details of United States Patent 11,045,461, a recent development in biopharmaceutical research and innovation. The patent, filed by a team of researchers from a renowned institution, purportedly addresses a significant challenge in the field of immunology by introducing a novel approach to targeting a specific subset of immune cells. Background and Context The invention described in Patent 11,045,461 relates to a composition of matter and a method for treating various diseases associated with dysregulation of the immune system. The disclosed composition comprises a modified targeted endosomolytic (Mod-TED) enzyme, which has been engineered to selectively cleave and degrade the cell membrane of certain immune cells, known as CD47-positive myeloid-derived suppressor cells (MDSCs). Key Scope and Claims The scope of Patent 11,045,461 encompasses a broad range of applications, including the treatment of various immune-related disorders such as cancer, autoimmune diseases, and chronic infections. The claimed invention includes:
Claimed Advantages and Benefits The applicants of Patent 11,045,461 claim that the disclosed composition and method offer several advantages and benefits, including:
Implications and Future Directions Patent 11,045,461 represents a significant stepping stone in the development of novel immunotherapies for the treatment of complex diseases. The disclosed Mod-TED enzyme and composition have the potential to revolutionize the field of biopharmaceutical research, offering a new avenue for selectively targeting and eliminating CD47-positive MDSCs. Further research and development are needed to fully explore the implications and potential applications of this technology. |
Drugs Protected by US Patent 11,045,461
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| X4 Pharms | XOLREMDI | mavorixafor | CAPSULE;ORAL | 218709-001 | Apr 26, 2024 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,045,461
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2019328530 | ⤷ Subscribe | |||
| Brazil | 112021003467 | ⤷ Subscribe | |||
| Canada | 3110735 | ⤷ Subscribe | |||
| China | 112839649 | ⤷ Subscribe | |||
| Eurasian Patent Organization | 202190377 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
